caffeine has been researched along with Fatty Liver, Nonalcoholic in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Caffeine intake is associated with a reduced risk developing non-alcoholic fatty liver disease (NAFLD), but the underlying molecular mechanisms remain to be fully elucidated." | 7.91 | Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. ( Akira, S; Cai, X; Fang, C; Fujiwara, N; Hao, S; Hayashi, S; Nishiguchi, S; Sakiyama, H; Sheng, J; Tsutsui, H; Wang, X; Yang, Q, 2019) |
| "Epigallocatechin-3-gallate (EGCG) and caffeine in tea exert anti-obesity effects and induces nonalcoholic fatty liver disease (NAFLD) amelioration." | 7.91 | Coadministration of epigallocatechin-3-gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats. ( An, HM; Huang, JA; Lin, HY; Liu, ZH; Ou, XC; Wen, BB; Xiong, YF; Yang, Z; Zhang, YB; Zhu, MZ, 2019) |
| "This study aimed to evaluate female adult offspring induced by prenatal caffeine exposure (PCE) are susceptible to non-alcoholic fatty liver disease (NAFLD) and to explore the underlying programming mechanisms." | 7.91 | Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBPα-SIRT1 pathway. ( Hu, S; Luo, H; Wang, H; Xia, L; Xu, D; Xu, Y; Yu, H, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is much more frequent and more severe, including cirrhosis, hepatocellular carcinoma in patients with type 2 diabetes." | 7.01 | Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-c ( Adibi, H; Hekmatdoost, A; Mansour, A; Merat, S; Mohajeri-Tehrani, MR; Poustchi, H; Qorbani, M; Samadi, M, 2021) |
| "Severe NAFLD appeared with higher Kleiner scores." | 5.40 | Intrauterine metabolic programming alteration increased susceptibility to non-alcoholic adult fatty liver disease in prenatal caffeine-exposed rat offspring. ( Chen, L; Huang, H; Liu, Y; Liu, Z; Ping, J; Shen, L; Wang, H; Wang, L; Wu, Y; Zhang, L, 2014) |
| "The association of CC with nonalcoholic fatty liver disease (NAFLD) has not been established." | 5.38 | Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. ( Calcagno, CJ; Harrison, SA; Jones, FJ; Molloy, JW; Torres, DM; Williams, CD, 2012) |
| "Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is the most common cause of primary liver disease." | 5.38 | Caffeine is protective in patients with non-alcoholic fatty liver disease. ( Birerdinc, A; Pawloski, L; Stepanova, M; Younossi, ZM, 2012) |
| "The CBT was applied to 48 patients with NAFLD." | 5.37 | Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. ( Fung, C; George, J; Katelaris, PH; Ngu, MC; Park, GJ; Seow, F; Wiseman, E, 2011) |
| " We used a combination of the keywords "coffee", "caffeine", "tea", "non-alcoholic fatty liver disease", "non-alcoholic steatohepatitis", "metabolic syndrome"." | 4.93 | Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. ( Del Rio, D; Godos, J; Grosso, G; Marventano, S; Mistretta, A; Pluchinotta, F; Salomone, F, 2016) |
| "Caffeine intake is associated with a reduced risk developing non-alcoholic fatty liver disease (NAFLD), but the underlying molecular mechanisms remain to be fully elucidated." | 3.91 | Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. ( Akira, S; Cai, X; Fang, C; Fujiwara, N; Hao, S; Hayashi, S; Nishiguchi, S; Sakiyama, H; Sheng, J; Tsutsui, H; Wang, X; Yang, Q, 2019) |
| "Epigallocatechin-3-gallate (EGCG) and caffeine in tea exert anti-obesity effects and induces nonalcoholic fatty liver disease (NAFLD) amelioration." | 3.91 | Coadministration of epigallocatechin-3-gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats. ( An, HM; Huang, JA; Lin, HY; Liu, ZH; Ou, XC; Wen, BB; Xiong, YF; Yang, Z; Zhang, YB; Zhu, MZ, 2019) |
| "This study aimed to evaluate female adult offspring induced by prenatal caffeine exposure (PCE) are susceptible to non-alcoholic fatty liver disease (NAFLD) and to explore the underlying programming mechanisms." | 3.91 | Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBPα-SIRT1 pathway. ( Hu, S; Luo, H; Wang, H; Xia, L; Xu, D; Xu, Y; Yu, H, 2019) |
| "The beneficial effect of caffeine-containing food on non-alcoholic fatty liver disease (NAFLD) has been widely reported." | 3.81 | Caffeine ameliorates high energy diet-induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway. ( Cao, LF; Chen, M; He, RR; Kurihara, H; Li, YF; Mao, GW; Tan, RR; Tsoi, B; Wang, GE; Wang, Q; Zhai, YJ; Zhang, SJ, 2015) |
| "Caffeine, the main component of coffee, has showed its protective effect on non-alcoholic fatty liver disease (NAFLD) in many studies." | 3.81 | Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. ( Chen, X; Dai, W; Hou, J; Liu, L; Wang, K; Zhang, W; Zheng, X, 2015) |
| "Non-alcoholic fatty liver disease (NAFLD) is much more frequent and more severe, including cirrhosis, hepatocellular carcinoma in patients with type 2 diabetes." | 3.01 | Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-c ( Adibi, H; Hekmatdoost, A; Mansour, A; Merat, S; Mohajeri-Tehrani, MR; Poustchi, H; Qorbani, M; Samadi, M, 2021) |
| " This study aimed to build a physiologically based pharmacokinetic (PBPK) model reflecting observed changes in physiological and molecular parameters relevant to drug disposition that are associated with MAFLD." | 2.82 | A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure. ( Newman, EM; Rowland, A, 2022) |
| "Caffeine was administered orally at a daily dose of 50 mg/kg body weight during the period of NASH induction to evaluate its ability to prevent disease development." | 1.91 | The antioxidant and anti-inflammatory activities of caffeine effectively attenuate nonalcoholic steatohepatitis and thioacetamide-induced hepatic injury in male rats. ( Acero-Hernández, C; Cardoso-Lezama, I; Galindo-Gómez, S; Muriel, P; Ramos-Tovar, E; Tsutsumi, V; Vargas-Pozada, EE, 2023) |
| "Caffeine treatment significantly decreased the elevated serum ALT, AST, and bilirubin and increased the reduced albumin level." | 1.48 | Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention. ( Ayoub, SE; Elkashefand, WF; Helal, MG; Ibrahim, TM, 2018) |
| "Metabolic syndrome is one of the most important health issues worldwide." | 1.46 | Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice. ( Baba, H; Morimoto, Y; Ogawa, H; Takahashi, T; Tsunematsu, T; Tsuneyama, K; Uehara, H; Watanabe, S, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) characterizes and predicts T2DM yet the relationship of coffee with this disorder remains unclear." | 1.42 | Associations of coffee consumption with markers of liver injury in the insulin resistance atherosclerosis study. ( Dickson, JC; Haffner, SM; Hamren, SJ; Hanley, AJ; Liese, AD; Lorenzo, C; Stiles, JK; Wagenknecht, LE; Watkins, SM, 2015) |
| "Severe NAFLD appeared with higher Kleiner scores." | 1.40 | Intrauterine metabolic programming alteration increased susceptibility to non-alcoholic adult fatty liver disease in prenatal caffeine-exposed rat offspring. ( Chen, L; Huang, H; Liu, Y; Liu, Z; Ping, J; Shen, L; Wang, H; Wang, L; Wu, Y; Zhang, L, 2014) |
| "The association of CC with nonalcoholic fatty liver disease (NAFLD) has not been established." | 1.38 | Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. ( Calcagno, CJ; Harrison, SA; Jones, FJ; Molloy, JW; Torres, DM; Williams, CD, 2012) |
| "Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is the most common cause of primary liver disease." | 1.38 | Caffeine is protective in patients with non-alcoholic fatty liver disease. ( Birerdinc, A; Pawloski, L; Stepanova, M; Younossi, ZM, 2012) |
| "The CBT was applied to 48 patients with NAFLD." | 1.37 | Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. ( Fung, C; George, J; Katelaris, PH; Ngu, MC; Park, GJ; Seow, F; Wiseman, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (66.67) | 24.3611 |
| 2020's | 9 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, Z | 1 |
| Wang, C | 1 |
| Yang, T | 1 |
| Gao, T | 1 |
| Wang, D | 1 |
| Zhao, X | 1 |
| Guo, X | 2 |
| Li, D | 1 |
| Kakiyama, G | 1 |
| Minowa, K | 1 |
| Rodriguez-Agudo, D | 1 |
| Martin, R | 1 |
| Takei, H | 1 |
| Mitamura, K | 1 |
| Ikegawa, S | 1 |
| Suzuki, M | 1 |
| Nittono, H | 1 |
| Fuchs, M | 1 |
| Heuman, DM | 1 |
| Zhou, H | 1 |
| Pandak, WM | 1 |
| Newman, EM | 1 |
| Rowland, A | 1 |
| Vargas-Pozada, EE | 1 |
| Ramos-Tovar, E | 1 |
| Acero-Hernández, C | 1 |
| Cardoso-Lezama, I | 1 |
| Galindo-Gómez, S | 1 |
| Tsutsumi, V | 1 |
| Muriel, P | 1 |
| Dranoff, JA | 1 |
| Zhang, C | 1 |
| Zhang, D | 1 |
| Huang, H | 2 |
| Lu, X | 1 |
| Shi, H | 1 |
| Liu, K | 1 |
| Zhang, R | 1 |
| Wang, H | 4 |
| Velázquez, AM | 1 |
| Roglans, N | 1 |
| Bentanachs, R | 1 |
| Gené, M | 1 |
| Sala-Vila, A | 1 |
| Lázaro, I | 1 |
| Rodríguez-Morató, J | 1 |
| Sánchez, RM | 1 |
| Laguna, JC | 1 |
| Alegret, M | 1 |
| Mansour, A | 1 |
| Mohajeri-Tehrani, MR | 1 |
| Samadi, M | 1 |
| Qorbani, M | 1 |
| Merat, S | 1 |
| Adibi, H | 1 |
| Poustchi, H | 1 |
| Hekmatdoost, A | 1 |
| Sewter, R | 1 |
| Heaney, S | 1 |
| Patterson, A | 1 |
| Watanabe, S | 1 |
| Takahashi, T | 1 |
| Ogawa, H | 1 |
| Uehara, H | 1 |
| Tsunematsu, T | 1 |
| Baba, H | 1 |
| Morimoto, Y | 1 |
| Tsuneyama, K | 1 |
| Helal, MG | 1 |
| Ayoub, SE | 1 |
| Elkashefand, WF | 1 |
| Ibrahim, TM | 1 |
| Fang, C | 1 |
| Cai, X | 1 |
| Hayashi, S | 1 |
| Hao, S | 1 |
| Sakiyama, H | 1 |
| Wang, X | 1 |
| Yang, Q | 1 |
| Akira, S | 1 |
| Nishiguchi, S | 1 |
| Fujiwara, N | 1 |
| Tsutsui, H | 1 |
| Sheng, J | 1 |
| Yang, Z | 1 |
| Zhu, MZ | 1 |
| Zhang, YB | 1 |
| Wen, BB | 1 |
| An, HM | 1 |
| Ou, XC | 1 |
| Xiong, YF | 1 |
| Lin, HY | 1 |
| Liu, ZH | 1 |
| Huang, JA | 1 |
| Hu, S | 2 |
| Xia, L | 1 |
| Luo, H | 1 |
| Xu, Y | 1 |
| Yu, H | 1 |
| Xu, D | 1 |
| He, B | 1 |
| Wen, Y | 1 |
| Wang, G | 1 |
| Hu, W | 1 |
| Magdalou, J | 1 |
| Chen, L | 2 |
| Saab, S | 1 |
| Mallam, D | 1 |
| Cox, GA | 1 |
| Tong, MJ | 1 |
| Wang, L | 1 |
| Shen, L | 1 |
| Ping, J | 1 |
| Zhang, L | 1 |
| Liu, Z | 1 |
| Wu, Y | 1 |
| Liu, Y | 1 |
| Zhang, SJ | 1 |
| Li, YF | 1 |
| Wang, GE | 1 |
| Tan, RR | 1 |
| Tsoi, B | 1 |
| Mao, GW | 1 |
| Zhai, YJ | 1 |
| Cao, LF | 1 |
| Chen, M | 1 |
| Kurihara, H | 1 |
| Wang, Q | 1 |
| He, RR | 1 |
| Dickson, JC | 1 |
| Liese, AD | 1 |
| Lorenzo, C | 1 |
| Haffner, SM | 1 |
| Watkins, SM | 1 |
| Hamren, SJ | 1 |
| Stiles, JK | 1 |
| Wagenknecht, LE | 1 |
| Hanley, AJ | 1 |
| Graeter, T | 1 |
| Niedermayer, PC | 1 |
| Mason, RA | 1 |
| Oeztuerk, S | 1 |
| Haenle, MM | 1 |
| Koenig, W | 1 |
| Boehm, BO | 1 |
| Kratzer, W | 1 |
| Zheng, X | 1 |
| Dai, W | 1 |
| Chen, X | 1 |
| Wang, K | 1 |
| Zhang, W | 1 |
| Liu, L | 1 |
| Hou, J | 1 |
| Marventano, S | 1 |
| Salomone, F | 1 |
| Godos, J | 1 |
| Pluchinotta, F | 1 |
| Del Rio, D | 1 |
| Mistretta, A | 1 |
| Grosso, G | 1 |
| Park, GJ | 1 |
| Wiseman, E | 1 |
| George, J | 1 |
| Katelaris, PH | 1 |
| Seow, F | 1 |
| Fung, C | 1 |
| Ngu, MC | 1 |
| Molloy, JW | 1 |
| Calcagno, CJ | 1 |
| Williams, CD | 1 |
| Jones, FJ | 1 |
| Torres, DM | 1 |
| Harrison, SA | 1 |
| Birerdinc, A | 1 |
| Stepanova, M | 1 |
| Pawloski, L | 1 |
| Younossi, ZM | 1 |
| Panchal, SK | 1 |
| Poudyal, H | 1 |
| Waanders, J | 1 |
| Brown, L | 1 |
| Anty, R | 1 |
| Marjoux, S | 1 |
| Iannelli, A | 1 |
| Patouraux, S | 1 |
| Schneck, AS | 1 |
| Bonnafous, S | 1 |
| Gire, C | 1 |
| Amzolini, A | 1 |
| Ben-Amor, I | 1 |
| Saint-Paul, MC | 1 |
| Mariné-Barjoan, E | 1 |
| Pariente, A | 1 |
| Gugenheim, J | 1 |
| Gual, P | 1 |
| Tran, A | 1 |
5 reviews available for caffeine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorp | 2022 |
Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects.
Topics: Caffeine; Coffee; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2023 |
Coffee Consumption and the Progression of NAFLD: A Systematic Review.
Topics: Caffeine; Coffee; Cross-Sectional Studies; Disease Progression; Female; Humans; Liver Cirrhosis; Mal | 2021 |
Impact of coffee on liver diseases: a systematic review.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Caffeine; Carcinoma, Hepatocell | 2014 |
Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies.
Topics: Caffeine; Coffee; Diet; Humans; Liver Cirrhosis; MEDLINE; Metabolic Syndrome; Non-alcoholic Fatty Li | 2016 |
1 trial available for caffeine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-c
Topics: Caffeine; Chlorogenic Acid; Coffee; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Met | 2021 |
21 other studies available for caffeine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Coffee peel extracts ameliorate non-alcoholic fatty liver disease
Topics: Adiponectin; Animals; Caffeine; Coffee; Diet, High-Fat; Fibroblast Growth Factors; Flavonoids; Liver | 2022 |
Coffee modulates insulin-hepatocyte nuclear factor-4α-Cyp7b1 pathway and reduces oxysterol-driven liver toxicity in a nonalcoholic fatty liver disease mouse model.
Topics: Animals; Caffeine; Cholesterol; Coffee; Cytochrome P450 Family 7; Disease Models, Animal; Hepatitis; | 2022 |
The antioxidant and anti-inflammatory activities of caffeine effectively attenuate nonalcoholic steatohepatitis and thioacetamide-induced hepatic injury in male rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Caffeine; Cytokines; Humans; Liver; Male; NF-E2-Rel | 2023 |
Cathepsin D mediates prenatal caffeine exposure-caused NAFLD susceptibility in male rat offspring by regulating autophagy.
Topics: Animals; Autophagy; Caffeine; Cathepsin D; Corticosterone; Female; Humans; Male; MicroRNAs; Non-alco | 2023 |
Effects of a Low Dose of Caffeine Alone or as Part of a Green Coffee Extract, in a Rat Dietary Model of Lean Non-Alcoholic Fatty Liver Disease without Inflammation.
Topics: Animals; Caffeine; Coffee; Diet, High-Fat; Dietary Fats; Dietary Supplements; Disease Models, Animal | 2020 |
Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice.
Topics: Aging; Animals; Caffeine; Coffee; Diabetes Mellitus, Type 2; Hyperlipidemias; Insulin-Secreting Cell | 2017 |
Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Caffeine; Cytoprotection; Diet, High-Fa | 2018 |
Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease.
Topics: Adipocytes; Animals; Caffeine; Diet, High-Fat; Disease Models, Animal; Hepatocytes; Interleukin-6; L | 2019 |
Coadministration of epigallocatechin-3-gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats.
Topics: Animals; Body Weight; Caffeine; Catechin; Diet, High-Fat; Dose-Response Relationship, Drug; Drug The | 2019 |
Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBPα-SIRT1 pathway.
Topics: Animals; Caffeine; CCAAT-Binding Factor; Dose-Response Relationship, Drug; Female; Non-alcoholic Fat | 2019 |
Prenatal caffeine exposure induces liver developmental dysfunction in offspring rats.
Topics: Animals; Caffeine; Corticosterone; Female; Fetal Development; Fetal Growth Retardation; Gene Express | 2019 |
Intrauterine metabolic programming alteration increased susceptibility to non-alcoholic adult fatty liver disease in prenatal caffeine-exposed rat offspring.
Topics: Algorithms; Animals; Blood Glucose; Body Weight; Caffeine; Central Nervous System Stimulants; Fatty | 2014 |
Caffeine ameliorates high energy diet-induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Caffeine; CREB-Binding Protein; Diet | 2015 |
Associations of coffee consumption with markers of liver injury in the insulin resistance atherosclerosis study.
Topics: Alanine Transaminase; alpha-2-HS-Glycoprotein; Aspartate Aminotransferases; Biomarkers; Caffeine; Co | 2015 |
Coffee consumption and NAFLD: a community based study on 1223 subjects.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Body Mass Index; Caffeine; Central Nervous System Sti | 2015 |
Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae.
Topics: Animals; Caffeine; Endoplasmic Reticulum Stress; Humans; Lipids; Lipogenesis; Liver; Non-alcoholic F | 2015 |
Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biopsy; Breath Tests; Caffeine; Case-Control S | 2011 |
Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis.
Topics: Age Factors; Alanine Transaminase; Body Mass Index; Caffeine; Coffee; Fatty Liver; Female; Glycated | 2012 |
Caffeine is protective in patients with non-alcoholic fatty liver disease.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Diet; Fatty Liver; Female; Humans; Liver; Male; Middle Age | 2012 |
Coffee extract attenuates changes in cardiovascular and hepatic structure and function without decreasing obesity in high-carbohydrate, high-fat diet-fed male rats.
Topics: Animals; Anti-Obesity Agents; Caffeine; Coffee; Diet, High-Fat; Dietary Sucrose; Diterpenes; Fatty L | 2012 |
Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery.
Topics: Adult; Bariatric Surgery; Biopsy; Cacao; Caffeine; Coffee; Cohort Studies; Cola; Comorbidity; Europe | 2012 |